To better meet customer demand, particularly in the Asia Pacific region, and to expand regional value creation, Sartorius is continuing construction of its new facility in Songdo, South Korea. Upon completion, cell culture media and sterile consumables will be produced. The facility will be completed by 2026 and will be operational by early 2027.
Speaking to media in Bengaluru, Dr René Fáber, CEO of Sartorius Stedim Biotech S.A. and Head of the Bioprocess Solutions Division at Sartorius AG who was on a two-day visit to India said, “Additionally, we have plans for the new location, situated in the heart of a biopharma park, include a technology centre for customer consulting and product demonstrations, as well as laboratory space.”
Dr Faber further noted, “North America and Asia are the key focal areas of the regional growth strategy. The USA is the world's largest market for bioprocess equipment and laboratory products. Yet because it is home to our main competitors for both company divisions, Sartorius formerly had a lower market share in this region than in Europe and Asia. By systematically strengthening its sales and service capacities, Sartorius has gained market share in North America in recent years, and intends to expand this further.”
To a question on growth drivers for the company in Asia, he said “The Asian market also offers significant growth potential for Sartorius. The drivers here are demographic change, increasing prosperity, rising government spending on healthcare and the expansion of the regional biopharmaceutical industry. To benefit from this dynamic development, Sartorius has significantly strengthened its presence in this region.”
Sartorius records more than 90 per cent of its sales revenue outside Germany; in a regional breakdown, EMEA and the Americas contribute the largest share, followed by the Asia Pacific region.
